Evan E. Opas

2.8k total citations · 1 hit paper
34 papers, 2.0k citations indexed

About

Evan E. Opas is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Evan E. Opas has authored 34 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Oncology and 9 papers in Genetics. Recurrent topics in Evan E. Opas's work include Estrogen and related hormone effects (7 papers), Chemokine receptors and signaling (6 papers) and Bone health and treatments (5 papers). Evan E. Opas is often cited by papers focused on Estrogen and related hormone effects (7 papers), Chemokine receptors and signaling (6 papers) and Bone health and treatments (5 papers). Evan E. Opas collaborates with scholars based in United States, Canada and United Kingdom. Evan E. Opas's co-authors include Ronald E. Diehl, Jilly F. Evans, John W. Gillard, Douglas K. Miller, Richard A. F. Dixon, Elaine Rands, Philip J. Vickers, Maurice B. Feinstein, John L. Humes and Gideon A. Rodan and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Evan E. Opas

34 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis

1990 622 citations Evan E. Opas et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Evan E. Opas United States	18	820	594	379	359	272	34	2.0k
Dilip Amin United States	14	529 0.6×	280 0.5×	93 0.2×	232 0.6×	67 0.2×	26	1.6k
Brigitte Fournier Switzerland	22	1.1k 1.4×	360 0.6×	106 0.3×	258 0.7×	139 0.5×	30	2.3k
Teresa Iantomasi Italy	21	683 0.8×	161 0.3×	139 0.4×	227 0.6×	146 0.5×	82	1.5k
Shigehisa Taketomi Japan	22	1.2k 1.4×	243 0.4×	152 0.4×	315 0.9×	39 0.1×	44	2.0k
Alexander Kirschenbaum United States	30	1.3k 1.6×	549 0.9×	99 0.3×	78 0.2×	212 0.8×	62	3.2k
Alice C. Levine United States	33	1.5k 1.9×	595 1.0×	117 0.3×	90 0.3×	229 0.8×	79	3.9k
Donald P. Cameron Australia	34	1.6k 1.9×	698 1.2×	32 0.1×	569 1.6×	279 1.0×	98	3.7k
Tohru Yamazaki Japan	18	702 0.9×	284 0.5×	51 0.1×	142 0.4×	213 0.8×	48	1.7k
Kimihiko Sano Japan	24	1.3k 1.6×	207 0.3×	33 0.1×	231 0.6×	341 1.3×	60	2.7k
D M Peehl United States	23	1.3k 1.6×	471 0.8×	55 0.1×	97 0.3×	113 0.4×	33	3.0k

Countries citing papers authored by Evan E. Opas

Since Specialization

Citations

This map shows the geographic impact of Evan E. Opas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan E. Opas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan E. Opas more than expected).

Fields of papers citing papers by Evan E. Opas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan E. Opas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan E. Opas. The network helps show where Evan E. Opas may publish in the future.

Co-authorship network of co-authors of Evan E. Opas

This figure shows the co-authorship network connecting the top 25 collaborators of Evan E. Opas. A scholar is included among the top collaborators of Evan E. Opas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan E. Opas. Evan E. Opas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmidt, Azriel, Robert Meißner, Michael A. Gentile, et al.. (2014). Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 143. 29–39. 17 indexed citations

Yuan, Ziqiang, et al.. (2014). Generation of mice encoding a conditional null allele of Gcm2. Transgenic Research. 23(4). 631–641. 9 indexed citations

Cai, Chaozhong, Cuifen Hou, John O’Neill, et al.. (2013). Discovery and SAR of 5-aminooctahydrocyclopentapyrrole-3a-carboxamides as potent CCR2 antagonists. Bioorganic & Medicinal Chemistry Letters. 24(4). 1239–1242. 5 indexed citations

Subasinghe, Nalin L., James C. Lanter, Evan E. Opas, et al.. (2012). A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists. Bioorganic & Medicinal Chemistry Letters. 23(4). 1063–1069. 17 indexed citations

Cai, Chaozhong, Fu‐An Kang, Cuifen Hou, et al.. (2012). Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists. Bioorganic & Medicinal Chemistry Letters. 23(1). 351–354. 6 indexed citations

Zhang, Xuqing, James C. Lanter, Chaozhong Cai, et al.. (2011). Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists. Bioorganic & Medicinal Chemistry Letters. 21(18). 5577–5582. 18 indexed citations

Zhang, Xuqing, Cuifen Hou, Evan E. Opas, et al.. (2011). Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists. Bioorganic & Medicinal Chemistry Letters. 21(20). 6042–6048. 8 indexed citations

Opas, Evan E., Pascale V. Nantermet, Robert R. Wilkening, et al.. (2009). Control of rat tail skin temperature regulation by estrogen receptor-beta selective ligand. Maturitas. 64(1). 46–51. 17 indexed citations

Opas, Evan E., Michael A. Gentile, Donald B. Kimmel, Gideon A. Rodan, & Azriel Schmidt. (2005). Estrogenic control of thermoregulation in ERαKO and ERβKO mice. Maturitas. 53(2). 210–216. 30 indexed citations

10.

Schmidt, Azriel, Robert L. Vogel, Su Jane Rutledge, et al.. (2005). Cross-talk between an activator of nuclear receptors-mediated transcription and the D1 dopamine receptor signaling pathway. Pharmacology Biochemistry and Behavior. 80(3). 379–385. 4 indexed citations

11.

Opas, Evan E., Su Jane Rutledge, Robert L. Vogel, Gideon A. Rodan, & Azriel Schmidt. (2004). Rat tail skin temperature regulation by estrogen, phytoestrogens and tamoxifen. Maturitas. 48(4). 463–471. 23 indexed citations

12.

Opas, Evan E., Michael A. Gentile, Jérôme Rossert, et al.. (2000). Parathyroid hormone and prostaglandin E2 preferentially increase luciferase levels in bone of mice harboring a luciferase transgene controlled by elements of the pro-α1(I) collagen promoter. Bone. 26(1). 27–32. 15 indexed citations

13.

Gil, Laurent Frédéric, Yongxin Han, Evan E. Opas, et al.. (1999). Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorganic & Medicinal Chemistry. 7(5). 901–919. 77 indexed citations

14.

Opas, Evan E., Su Jane Rutledge, Ellis E. Golub, et al.. (1997). Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochemical Pharmacology. 54(6). 721–727. 27 indexed citations

15.

Balena, R., Brian C. Toolan, M. Shea, et al.. (1993). The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.. Journal of Clinical Investigation. 92(6). 2577–2586. 316 indexed citations

16.

Davies, Philip R., Bonnie M. Ashe, Robert J. Bonney, et al.. (1991). The Discovery and Biologic Properties of Cephalosporin‐Based Inhibitors of PMN Elastase. Annals of the New York Academy of Sciences. 624(1). 219–229. 24 indexed citations

17.

Opas, Evan E., Pam S. Dellea, D. Fletcher, Philip R. Davies, & John L. Humes. (1991). The in Vitro and in Vivo Recovery of PMN Elastase:Beta‐Lactam Inhibitor Complexes by Cation Exchange Chromatography. Annals of the New York Academy of Sciences. 624(1). 348–349. 2 indexed citations

18.

Opas, Evan E., Lawrence W. Argenbright, & John L. Humes. (1989). An enzymatic method for distinguishing the stereoisomers of 12-hydroxyeicosatetraenoic acid in human epidermis and psoriatic scale. British Journal of Dermatology. 120(1). 49–58. 11 indexed citations

19.

Meurer, Roger, Evan E. Opas, & John L. Humes. (1988). Effects of cyclooxygenase and lipoxygenase inhibitors on inflammation associated with oxazolone-induced delayed hypersensitivity. Biochemical Pharmacology. 37(18). 3511–3514. 22 indexed citations

20.

Bonney, Robert J., P. M. Davies, Harry W. Dougherty, et al.. (1987). Biochemical and biological activities of 2,3-dihydro-6-[3-(2-hydroxymethyl)phenyl-2-propenyl]-5-benzofuranol (L-651,896), a novel topical anti-inflammatory agent. Biochemical Pharmacology. 36(22). 3885–3891. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact